Head to Head Analysis: Aurinia Pharmaceuticals (AUPH) and Its Rivals

Aurinia Pharmaceuticals (NASDAQ: AUPH) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Aurinia Pharmaceuticals to similar companies based on the strength of its risk, valuation, dividends, earnings, profitability, institutional ownership and analyst recommendations.

Earnings and Valuation

This table compares Aurinia Pharmaceuticals and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Aurinia Pharmaceuticals $170,000.00 -$23.29 million -3.67
Aurinia Pharmaceuticals Competitors $284.49 million $34.10 million 77.29

Aurinia Pharmaceuticals’ rivals have higher revenue and earnings than Aurinia Pharmaceuticals. Aurinia Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Aurinia Pharmaceuticals has a beta of 2.35, meaning that its stock price is 135% more volatile than the S&P 500. Comparatively, Aurinia Pharmaceuticals’ rivals have a beta of 5.98, meaning that their average stock price is 498% more volatile than the S&P 500.

Insider and Institutional Ownership

28.1% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 17.3% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares Aurinia Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals -18,089.02% -25.56% -20.72%
Aurinia Pharmaceuticals Competitors -5,310.77% -218.27% -39.48%

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aurinia Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals 0 0 6 0 3.00
Aurinia Pharmaceuticals Competitors 877 3245 11730 233 2.70

Aurinia Pharmaceuticals currently has a consensus price target of $12.00, indicating a potential upside of 147.42%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.33%. Given Aurinia Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe Aurinia Pharmaceuticals is more favorable than its rivals.


Aurinia Pharmaceuticals rivals beat Aurinia Pharmaceuticals on 7 of the 12 factors compared.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit